WallStreetZenWallStreetZen

NASDAQ: APM
Aptorum Group Ltd Stock

$8.70-0.15 (-1.69%)
Updated Mar 27, 2024
APM Price
$8.70
Fair Value Price
N/A
Market Cap
$45.08M
52 Week Low
$1.35
52 Week High
$17.49
P/E
-2.36x
P/B
2.06x
P/S
8.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.20M
Earnings
-$13.40M
Gross Margin
7.3%
Operating Margin
-1,108.91%
Profit Margin
-1,117%
Debt to Equity
0.08
Operating Cash Flow
-$12M
Beta
0.63
Next Earnings
Apr 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

APM Overview

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

APM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
APM is good value based on its book value relative to its share price (2.06x), compared to the US Biotechnology industry average (6.2x)
P/B vs Industry Valuation
APM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more APM due diligence checks available for Premium users.

Be the first to know about important APM news, forecast changes, insider trades & much more!

APM News

Valuation

APM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.36x
Industry
14.3x
Market
44.45x

APM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.06x
Industry
6.2x
APM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

APM's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
APM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
APM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$14.4M
Liabilities
$1.6M
Debt to equity
0.08
APM's short-term assets ($1.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APM's short-term assets ($1.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
APM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

APM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
APM$45.08M-1.69%-2.36x2.06x
CADL$44.54M+3.36%-1.41x1.93x
NRXP$44.48M+2.71%-1.06x-7.15x
TARA$45.74M-3.61%-1.12x0.67x
ESLA$45.76M-0.79%-0.43x5.06x

Aptorum Group Stock FAQ

What is Aptorum Group's quote symbol?

(NASDAQ: APM) Aptorum Group trades on the NASDAQ under the ticker symbol APM. Aptorum Group stock quotes can also be displayed as NASDAQ: APM.

If you're new to stock investing, here's how to buy Aptorum Group stock.

What is the 52 week high and low for Aptorum Group (NASDAQ: APM)?

(NASDAQ: APM) Aptorum Group's 52-week high was $17.49, and its 52-week low was $1.35. It is currently -50.26% from its 52-week high and 544.44% from its 52-week low.

How much is Aptorum Group stock worth today?

(NASDAQ: APM) Aptorum Group currently has 5,181,697 outstanding shares. With Aptorum Group stock trading at $8.70 per share, the total value of Aptorum Group stock (market capitalization) is $45.08M.

Aptorum Group stock was originally listed at a price of $143.50 in Dec 18, 2018. If you had invested in Aptorum Group stock at $143.50, your return over the last 5 years would have been -93.94%, for an annualized return of -42.91% (not including any dividends or dividend reinvestments).

How much is Aptorum Group's stock price per share?

(NASDAQ: APM) Aptorum Group stock price per share is $8.70 today (as of Mar 27, 2024).

What is Aptorum Group's Market Cap?

(NASDAQ: APM) Aptorum Group's market cap is $45.08M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aptorum Group's market cap is calculated by multiplying APM's current stock price of $8.70 by APM's total outstanding shares of 5,181,697.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.